Back to top
more

Halozyme Therapeutics, Inc. (HALO)

(Real Time Quote from BATS)

$19.54 USD

19.54
588,381

-0.43 (-2.15%)

Updated Jan 21, 2020 03:11 PM ET

Add to portfolio

3-Hold     3    

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1
2
3
4
5
S&P
Strong Buy
Buy
Hold
Sell
Strong Sell
500
24.66%
17.94%
9.57%
5.30%
2.19%
10.75%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

D Value | F Growth | A Momentum | F VGM

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

View All Zacks #1 Ranked Stocks

Trades from $1

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Company Summary

San Diego, CA-based Halozyme Therapeutics is a biopharmaceutical company, focused on the development and commercialization of novel treatments for oncology indications by targeting tumor microenvironment. The company also licenses its novel drug delivery technology, ENHANZE, for subcutaneous administration of drugs.

The company’s ENHANZE drug delivery technology helps in developing subcutaneous administration of drugs. Several companies including Roche, Takeda, J&J, AbbVie, Lilly, Bristol-Myers and others are using this technology for developing subcutaneous formulation of their currently marketed drugs. The company has nine collaborations and three marketed partnered drugs ...

General Information

Halozyme Therapeutics, Inc.

11388 SORRENTO VALLEY ROAD

SAN DIEGO, CA 92121

Phone: 858-794-8889

Fax: 858-704-8311

Web: http://www.halozyme.com

Email: ir@halozyme.com

Industry Medical - Biomedical and Genetics
Sector Medical
Fiscal Year End December
Last Reported Quarter 12/31/2019
Next EPS Date 2/20/2020

EPS Information

Current Quarter EPS Consensus Estimate -0.15
Current Year EPS Consensus Estimate -0.42
Estimated Long-Term EPS Growth Rate NA
Next EPS Report Date 2/20/2020

Price and Volume Information

Zacks Rank Premium
Yesterday's Close 19.97
52 Week High 20.50
52 Week Low 14.61
Beta 1.86
20 Day Moving Average 1,311,729.25
Target Price Consensus 20.17

HALO

% Price Change
4 Week 8.83
12 Week 33.76
YTD 12.63
% Price Change Relative to S&P 500
4 Week 4.77
12 Week 20.93
YTD 10.59
Share Information
Shares Outstanding (millions) 146.54
Market Capitalization (millions) 2,926.40
Short Ratio NA
Last Split Date NA
Dividend Information
Dividend Yield 0.00%
Annual Dividend $0.00
Payout Ratio NA
Change in Payout Ratio NA
Last Dividend Payout / Amount NA / $0.00

Fundamental Ratios

P/E
P/E (F1) 37.21
Trailing 12 Months NA
PEG Ratio NA
EPS Growth
vs. Previous Year 10.53%
vs. Previous Quarter -70.00%
   
Sales Growth
vs. Previous Year 80.90%
vs. Previous Quarter 18.09%
   
Price Ratios
Price/Book 11.91
Price/Cash Flow NA
Price / Sales 14.45
ROE
12/31/19 NA
9/30/19 -15.76
6/30/19 -16.97
ROA
12/31/19 NA
9/30/19 -9.65
6/30/19 -9.89
Current Ratio
12/31/19 NA
9/30/19 3.17
6/30/19 2.89
Quick Ratio
12/31/19 NA
9/30/19 2.83
6/30/19 2.57
Operating Margin
12/31/19 NA
9/30/19 -19.73
6/30/19 -23.53
Net Margin
12/31/19 NA
9/30/19 -19.73
6/30/19 -23.53
Pre-Tax Margin
12/31/19 NA
9/30/19 -19.55
6/30/19 -23.34
Book Value
12/31/19 NA
9/30/19 1.68
6/30/19 1.79
Inventory Turnover
12/31/19 NA
9/30/19 1.03
6/30/19 0.44
Debt-to-Equity
12/31/19 NA
9/30/19 0.04
6/30/19 0.05
Debt to Capital
12/31/19 NA
9/30/19 3.66
6/30/19 5.14